Navigation Links
Federal Trade Commission Clears Kyphon's Acquisition of Non-Vertebroplasty Spine-Related Assets of Disc-O-Tech
Date:9/17/2007

SUNNYVALE, Calif., Sept. 17 /PRNewswire-FirstCall/ -- Kyphon Inc. (Nasdaq: KYPH) announced today that it has obtained clearance from the Federal Trade Commission (FTC) and U.S. Department of Justice under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (as amended) with respect to its acquisition of the non-vertebroplasty spine-related assets and associated intellectual property rights of Disc-O-Tech Medical Technologies, Ltd., a privately held Israeli company, and its U.S. subsidiary. This clearance relates to one of two definitive agreements entered into with Disc-O-Tech in December 2006.

Completion of this acquisition, which includes the B-Twin(TM) Expandable Spinal System for use in minimally invasive fusion procedures, remains subject to obtaining approvals of antitrust authorities in other relevant jurisdictions. Kyphon expects to complete the acquisition later this year.

About Kyphon Inc.

Kyphon develops and markets medical devices designed to restore and preserve spinal function and diagnose the source of low back pain using minimally invasive technologies. The company's products are used in balloon kyphoplasty for the treatment of spinal compression fractures caused by osteoporosis or cancer, in the Functional Anaesthetic Discography(TM) (F.A.D.(TM)) procedure for diagnosing the source of low back pain, and in the Interspinous Process Decompression (IPD(R)) procedure for treating the symptoms of lumbar spinal stenosis. More information about the company and its products can be found at http://www.kyphon.com and its balloon kyphoplasty patient education Web site, http://www.spinalfracture.com.

Kyphon and IPD are registered trademarks, and Functional Anaesthetic Discography and F.A.D. are trademarks, of Kyphon Inc. Disc-O-Tech, B-Twin and Confidence are trademarks of Disc-O-Tech.

Forward-Looking Statements

This press release contains forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, about the completion of the proposed acquisition. Forward-looking statements are based on management's current preliminary expectations and are subject to risks, uncertainties and assumptions, which may cause the company's actual results to differ materially from the statements contained herein. Factors that could cause actual results to differ materially from management's current expectations include, without limitation, the potential inability to obtain the regulatory approvals and clearances required to complete the acquisition, or to do so in a timely manner. Additional factors that may affect future results are contained in Kyphon's filings with the SEC, which are available at the SEC's website http://www.sec.gov. Kyphon undertakes no obligation to release publicly any revisions to any forward-looking statements contained herein to reflect events or circumstances after the date hereof.

KYPHG


'/>"/>
SOURCE Kyphon Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Federal bioenergy lab will give Wisconsin a chance to shine
2. Federal bill would set healthcare IT standards
3. Bill would provide federal aid for healthcare IT
4. Early Stage 10: The nuances of federal laws
5. Wisconsin can offer what a federal energy research lab needs
6. Medical technology firm lands $100K federal grant
7. New firm to help companies land federal dollars
8. Wisconsin firms urged to pursue federal SBIR dollars
9. UW-Eau Claire wins $500,000 federal science grant
10. Venture-backed firms could become eligible for federal SBIR grants
11. Federal grant-winning tips coming to Milwaukee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2017)... (PRWEB) , ... January 23, 2017 , ... ... replacement at the Caribbean Neurosciences Symposium (CANS) annual meeting in Montego Bay, Jamaica ... technology and host a hands-on workshop for surgeons to experience the simplicity of ...
(Date:1/21/2017)... Jan. 20, 2017 Interpace Diagnostics Group, ... that provides clinically useful molecular diagnostic tests and ... into a securities purchase agreement with three  institutional ... of common stock in a registered direct offering.  ... agreed to sell to the same investors warrants ...
(Date:1/20/2017)... YORK , January 20, 2017 ... current market conditions have influenced the most recent performances ... Therapeutics Inc. (NASDAQ: RGLS ), Abeona Therapeutics ... (NASDAQ: TBPH ), and Sage Therapeutics Inc. ... research report by Grand View Research, global Biotech market size is ...
(Date:1/19/2017)... 19, 2017  Market Research Future has a half cooked research ... Biopsy is growing rapidly and expected to reach USD 450 Million ... ... Biopsy Market has been assessed as a swiftly growing market and ... in the coming future. There has been a tremendous growth in ...
Breaking Biology Technology:
(Date:12/15/2016)... Germany , December 15, 2016 ... provider, today announced an agreement with NuData Security, an ... forces. The partnership will enable clients to focus on good ... local data protection regulation. ... In order to provide a one-stop fraud ...
(Date:12/15/2016)... 15, 2016 Advancements in biometrics ... wellness and wellbeing (HWW), and security of ... new passenger vehicles begin to feature fingerprint ... heart beat monitoring, brain wave monitoring, stress ... and pulse detection. These will be driven ...
(Date:12/12/2016)... , Dec. 12, 2016  Researchers at ... possibilities for graphene by combining the material with ... highly sensitive pressure detector able to sense pulse, ... a small spider.  The research ... can be read here:  http://science.sciencemag.org/content/354/6317/1257 ...
Breaking Biology News(10 mins):